Fluid Therapy Physiology: The Science Behind Every Drop

Starling forces, osmolality and tonicity, crystalloid composition tables (LRS, NaCl 0.9%, Plasmalyte), colloids, the glycocalyx model, and the acid-base implications of every fluid choice.

Introduction: Why the Fluid You Choose Matters

Fluid therapy is the commonest therapeutic intervention in veterinary medicine — and one of the most poorly understood. The choice between 0.9% saline and a balanced isotonic crystalloid, between a crystalloid and a colloid, between a maintenance and a replacement fluid, is not arbitrary. Each fluid has a specific composition, a specific distribution within the body compartments, and specific metabolic consequences.

This article builds from first principles — the body fluid compartments, Starling forces (both classic and revised), osmolality and tonicity — to a practical, physiologically grounded guide to fluid selection. We include detailed composition tables for every commonly used veterinary fluid and discuss the acid-base implications of each.

Body Fluid Compartments: Where the Water Lives

The distribution of an infused fluid between these compartments depends on its tonicity and composition. Isotonic crystalloids (e.g., LRS, 0.9% saline) distribute primarily to the ECF — approximately 75% to the interstitium and 25% to the plasma within 30 minutes of infusion. This is why crystalloids are volume-expanders but relatively inefficient plasma-volume expanders — 1 litre of isotonic crystalloid adds only ~250 mL to the plasma volume.

Starling Forces: The Revised Model, Not What You Learned in School

The Classic Starling Equation (1896)

The classic model predicted that fluid is filtered at the arteriolar end of the capillary (where P_c > π_c) and reabsorbed at the venular end (where π_c > P_c), with the lymphatics draining the excess. This model assumed that π_i is negligible — an assumption now known to be WRONG.

The Revised Starling Principle (The Glycocalyx Model, 2010s)

The endothelial glycocalyx — a 0.5–1.0 μm thick layer of proteoglycans, glycosaminoglycans, and adsorbed plasma proteins lining the endothelial surface — fundamentally changes the Starling model. The glycocalyx acts as a molecular sieve: the oncotic pressure gradient that matters is not between plasma and interstitium, but between plasma and the SUB-GLYCOCALYX space (the narrow clefts through which fluid is filtered).

The clinical implication is profound: under the revised model, there is NO steady-state reabsorption of fluid at the venular end of the capillary. Net filtration occurs along the ENTIRE capillary, and ALL filtered fluid is returned to the circulation via the lymphatics. This explains why interstitial oedema develops when lymphatic drainage is impaired (e.g., after lymph node dissection) or when the glycocalyx is damaged (e.g., in sepsis, where inflammatory mediators degrade the glycocalyx, increasing permeability).

Osmolality, Tonicity, and the Fluid Shift

Osmolality vs Osmolarity

Osmolality (mOsm/kg H₂O) measures solute particles per kilogram of water — the physiologically relevant measure because it is independent of temperature and the volume occupied by solutes. Osmolarity (mOsm/L) measures solute particles per litre of solution — used in clinical fluid labelling. For dilute solutions, they are nearly identical.

Tonicity — The Clinically Relevant Measure

Tonicity is 'effective osmolality' — it is determined ONLY by solutes that CANNOT freely cross cell membranes (effective osmoles: Na⁺, glucose, mannitol). Solutes that freely cross cell membranes (INEFFECTIVE osmoles: urea, ethanol) contribute to osmolality but NOT to tonicity because they equilibrate across the membrane and do not create a sustained osmotic gradient.

This distinction is clinically critical: a patient with severe azotaemia (BUN >200 mg/dL) has an elevated measured osmolality but NORMAL tonicity, because urea freely enters cells. No fluid shifts occur. In contrast, a patient with hypernatremia has elevated tonicity → water shifts out of cells → cellular dehydration → neurological signs. The clinical approach is completely different.

Crystalloid Fluids: Composition and Clinical Choice

Why 0.9% Saline Causes Hyperchloraemic Metabolic Acidosis

0.9% saline contains 154 mEq/L of BOTH Na⁺ and Cl⁻ — compared to plasma Na⁺ of ~140 and Cl⁻ of ~105. The excess Cl⁻ (154 vs 105 ~49 mEq/L extra) dilutes plasma bicarbonate via the strong ion difference (SID) mechanism. According to Stewart's physicochemical approach to acid-base, the plasma SID = [Na⁺] − [Cl⁻] ≈ 35 in health. Infusing a fluid with SID = 0 (Na⁺ − Cl⁻ = 154 − 154 = 0) progressively REDUCES plasma SID → metabolic acidosis. Balanced crystalloids have a higher SID (LRS ≈ 21, Plasmalyte ≈ 42) and produce minimal acid-base disturbance.

Colloids: When Bigger Is Better — Temporarily

Colloids are large molecules (MW >30,000 Da) that remain primarily in the intravascular space because the intact capillary membrane is impermeable to them. They generate oncotic pressure, drawing fluid from the interstitium into the plasma. The volume-expanding effect of a colloid is approximately 1:1 (1 mL colloid expands plasma volume by ~1 mL), compared to approximately 1:4 for crystalloids.

Clinical Framework: Choosing the Right Fluid

1. Is the patient hypovolaemic? (Tachycardia, prolonged CRT, weak pulses, hypotension) → Balanced isotonic crystalloid (LRS, Plasmalyte) at 10–20 mL/kg bolus over 15–20 min (± 5 mL/kg if cardiac disease). Reassess. Repeat if needed.
2. Is the patient dehydrated but normovolaemic? (Tacky mucous membranes, skin tent, weight loss, concentrated urine) → Replacement fluids (balanced crystalloid) at calculated deficit over 12–24 hours: Deficit (L) = % dehydration × body weight (kg).
3. Is the patient hypernatremic? (Na⁺ >155 mEq/L) → Free water replacement (D5W, 0.45% NaCl) — correct SLOWLY (not >0.5–1 mEq/L/h) to avoid cerebral oedema.
4. Is the patient hyponatremic? (Na⁺ <140 mEq/L) → 0.9% saline or hypertonic saline — correct SLOWLY (not >0.5–1 mEq/L/h) to avoid central pontine myelinolysis.
5. Is the patient hypokalaemic? → Add KCl to fluids (max 0.5 mEq/kg/h; max concentration 60 mEq/L in peripheral line).
6. Is the patient hypoglycaemic? → 2.5% or 5% dextrose in fluids (provides ~85–170 kcal/L). NOT for sole nutrition — dextrose alone is inadequate.

Acid-Base Physiology and Advanced Fluid Selection

Stewart's Physicochemical Approach to Acid-Base

Traditional acid-base analysis (Henderson-Hasselbalch) describes pH as determined by PCO₂ and [HCO₃⁻]. Stewart's approach recognises that [H⁺] and [HCO₃⁻] are DEPENDENT variables — they change in response to three INDEPENDENT variables: (1) PCO₂ (respiratory component), (2) the strong ion difference (SID = [Na⁺] + [K⁺] + [Ca²⁺] + [Mg²⁺] − [Cl⁻] − [lactate] − [other strong anions]), and (3) total weak acid concentration (A_TOT — primarily albumin and phosphate). A decreased SID produces metabolic acidosis (e.g., hyperchloraemia, dilutional acidosis from large-volume 0.9% saline). An increased SID produces metabolic alkalosis (e.g., hypochloraemia from vomiting of gastric contents). This framework explains the 'hyperchloraemic metabolic acidosis' of saline resuscitation — it is a SID acidosis, not a bicarbonate loss.

Fluid Therapy in Specific Clinical Scenarios

Diabetic Ketoacidosis (DKA)

DKA patients have a profound anion-gap metabolic acidosis from ketone bodies (acetoacetate, β-hydroxybutyrate) PLUS variable degrees of dilutional acidosis from prior 0.9% saline administration. Fluid choice matters: Plasmalyte-148 (SID 42) gently increases SID and allows endogenous regeneration of bicarbonate as ketones are cleared by insulin therapy. LRS is acceptable. 0.9% saline WORSENS the acidosis by lowering SID further — AVOID unless the patient is also hyponatremic. Monitor: electrolytes Q4–6h (K⁺ shifts intracellularly with insulin → hypokalaemia is the most dangerous complication of DKA treatment). Phosphate supplementation may be needed.

Urethral Obstruction in Cats

Post-obstructive diuresis follows relief of urethral obstruction. The key electrolyte disturbance is HYPERKALEMIA (from impaired renal K⁺ excretion + leakage from damaged bladder mucosa) — treat with IV calcium gluconate (cardioprotective), IV regular insulin + dextrose (shifts K⁺ intracellularly), and IV NaHCO₃ if severely acidotic. Fluid of choice: Plasmalyte or LRS (balanced isotonic — these contain 4–5 mEq/L K⁺ which is beneficial once the hyperkalemia is resolved, as total body K⁺ is usually depleted). Monitor urine output — post-obstructive diuresis can produce 5–10 mL/kg/h and must be matched with appropriate IV fluids.

Heat Stroke

Heat stroke → systemic inflammation → endothelial glycocalyx degradation → capillary leak → hypovolaemia + interstitial oedema. The fluid of choice is balanced isotonic crystalloids (LRS or Plasmalyte) — colloids offer no advantage when the glycocalyx is breached. Aggressive cooling (NOT ice baths — vasoconstriction slows heat loss; use evaporative cooling with fans and room-temperature water) and supportive care. Monitor for DIC, acute kidney injury, and neurological deterioration. The glycocalyx damage explains why these patients require massive fluid volumes (>90 mL/kg in the first hours) yet rapidly develop peripheral oedema — the fluid is leaking out of damaged capillaries nearly as fast as it is infused.

Transfusion Medicine: The Physiology of Blood Products

Blood transfusion is essentially a specialised form of fluid therapy — and its physiology builds directly on the principles of Starling forces, oncotic pressure, and oxygen delivery we have already discussed. Understanding what each blood product provides (and doesn't provide) is essential for appropriate component therapy.

Packed Red Blood Cells (pRBCs) — Oxygen-Carrying Capacity

One unit of canine pRBCs (~200 mL from a 25 kg donor) increases the recipient's PCV by approximately 5–8% (or haemoglobin by 1–2 g/dL), assuming no ongoing haemorrhage or haemolysis. The pRBC unit has a haematocrit of ~70–80% and is stored in CPDA-1 anticoagulant at 4°C. Stored RBCs undergo the 'storage lesion': progressive depletion of 2,3-DPG (increases haemoglobin-oxygen affinity → shifts the oxyhaemoglobin dissociation curve LEFT → reduces oxygen unloading at the tissue level), reduced deformability, and accumulation of pro-inflammatory mediators. 2,3-DPG recovers within 24 hours post-transfusion in vivo. Transfusion trigger: generally PCV <15–20% with clinical signs of anaemia (tachycardia, tachypnoea, weakness, elevated lactate) — NOT a number alone. The decision to transfuse is a clinical one, informed by but not dictated by the PCV.

Fresh Frozen Plasma (FFP) — Coagulation Factors and Albumin

FFP contains all coagulation factors, albumin, antithrombin III, and other plasma proteins. It does NOT provide meaningful oxygen-carrying capacity (no RBCs) or platelet function. Indications: (1) Coagulopathy with active bleeding (e.g., rodenticide toxicity before vitamin K1 has taken effect, DIC with haemorrhage, severe hepatic failure). (2) Replacement of specific factor deficiencies (von Willebrand factor in vWD — though cryoprecipitate is preferred if available). (3) Hypoalbuminaemia with clinical signs (effusion, oedema) when albumin transfusion is indicated but canine albumin is unavailable. Dose: 10–15 mL/kg, administered over 2–4 hours. FFP does NOT correct thrombocytopenia — for platelet deficiency, use fresh whole blood or platelet-rich plasma.

Transfusion Reactions — What Happens When the Physiology Fights Back

Acute haemolytic transfusion reactions (AHTR) are the most feared complication: pre-existing recipient antibodies (from an incompatible previous transfusion — dogs develop strong DEA 1.1 antibodies within 7–10 days of an incompatible transfusion) bind donor RBCs → complement activation → intravascular haemolysis → haemoglobinuria → acute kidney injury → DIC → cardiovascular collapse. Prevention: (1) ALWAYS crossmatch before transfusion, even in first-time recipients if they have received a previous transfusion. (2) Use DEA 1.1-negative donors for all recipients (universal donor). (3) In cats, type B cats have naturally occurring, high-titre anti-A antibodies → transfusion of type A blood into a type B cat causes a SEVERE acute haemolytic reaction with mortality >50%. ALWAYS blood-type cats before transfusion. Type AB cats receive type A blood if AB is unavailable. Feline blood typing cards (RapidVet-H Feline) provide bedside results in <5 minutes.

Electrolyte Disorders: The Fluid That Follows the Solute

Sodium — The Osmolality Driver

Na⁺ and its accompanying anions (Cl⁻ and HCO₃⁻) account for approximately 95% of plasma osmolality. Hyponatremia (Na⁺ <140 mEq/L) → water shifts into cells → cellular swelling. If acute and severe (<120 mEq/L) → cerebral oedema → neurological signs. Hypernatremia (Na⁺ >155 mEq/L) → water shifts out of cells → cellular dehydration. If chronic → brain cells generate idiogenic osmoles (inositol, taurine, glutamine) to protect cell volume → if extracellular Na⁺ is then corrected too rapidly (>0.5 mEq/L/h) → water rushes into brain cells that still contain these osmoles → CEREBRAL OEDEMA → osmotic demyelination syndrome.

Potassium — The Resting Potential Regulator

The ratio of intracellular to extracellular [K⁺] is the primary determinant of the resting membrane potential. Hypokalaemia (K⁺ <3.5 mEq/L) → hyperpolarisation → reduced excitability → muscle weakness, ileus, and ECG changes (flattened T waves, prominent U waves, ST depression). Causes: GI loss (vomiting, diarrhoea — the commonest), renal loss (diuretics, CKD in cats, hyperaldosteronism), insulin administration (shifts K⁺ intracellularly). Management: K⁺ supplementation (IV: max 0.5 mEq/kg/h; PO: potassium gluconate). NEVER give KCl as an IV bolus — fatal cardiac arrhythmia.

Hyperkalemia (K⁺ >5.5 mEq/L) → depolarisation → initially INCREASED excitability (membrane closer to threshold), then DECREASED excitability (Na⁺ channel inactivation) → ECG changes: peaked T waves → flattened P waves → wide QRS → sine wave → asystole. Causes: reduced renal excretion (obstructive uropathy in cats, anuric renal failure, hypoadrenocorticism — Addison's disease), massive tissue breakdown (rhabdomyolysis, tumour lysis), iatrogenic (excessive K⁺ supplementation). Management: (1) Cardioprotection — IV calcium gluconate 10% (0.5–1 mL/kg over 10 min — stabilises myocardial membrane, does NOT lower K⁺). (2) Shift K⁺ intracellularly — regular insulin (0.5 U/kg IV) + dextrose (2 g per unit of insulin), or NaHCO₃ (1–2 mEq/kg IV if acidotic), or β2-agonist (salbutamol/albuterol nebulised — limited evidence in veterinary). (3) Eliminate K⁺ from the body — IV fluids to promote renal excretion, furosemide if renal function present, haemodialysis in refractory cases.

Frequently asked questions

Self-check quiz

Test yourself. Answers are below each question — cover them first if you are studying.